TITLE

Novelty seeking and harm avoidance in Parkinson's disease: effects of asymmetric dopamine deficiency

AUTHOR(S)
Tomer, R.; Aharon-Peretz, J.
PUB. DATE
July 2004
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Jul2004, Vol. 75 Issue 7, p972
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Objectives: Although changes in novelty seeking and harm avoidance have been reported among patients with Parkinson's disease (PD), the findings regarding the neurochemical correlates of such changes are inconsistent. This study was designed to examine the hypothesis that different patterns of motor and neurochemical asymmetry in PD may have contributed to the conflicting results.Methods: Forty PD patients (divided into two groups according to initial asymmetry in dopamine deficit: left hemisphere, n = 22; right hemisphere, n = 18) and 17 age matched healthy controls completed the Tridimensional Personality Questionnaire (Cloninger, 1987).Results: Only patients with greater dopamine loss in the left hemisphere showed reduced novelty seeking, whereas only patients with reduced dopamine in the right hemisphere reported higher harm avoidance than matched healthy controls. Novelty seeking was not associated with disease duration, current motor symptoms, or medication, whereas harm avoidance was significantly correlated only with the severity of bradykinesia and depression.Conclusions: Approach and avoidance reflect different patterns of dopaminergic asymmetry. Whereas reduced novelty seeking reflects deficit in the mesolimbic branch of ascending dopamine transmission in the left hemisphere, increased harm avoidance is associated with greater dopamine loss in the right striatum.
ACCESSION #
13927731

 

Related Articles

  • Cytotoxicity of chloral-derived β-carbolines is not specific towards neuronal nor dopaminergic cells. Storch, A.; Hwang, Y.-I.; Bringmann, G.; Feineis, D.; Ott, S.; Brückner, R.; Schwarz, J. // Journal of Neural Transmission;Dec2006, Vol. 113 Issue 12, p1895 

    β-Carbolines structurally related to the selective dopaminergic neurotoxin 1-methyl-4- phenylpyridinium (MPP+) may contribute to dopaminergic neurodegeneration in Parkinson’s disease. The chloral-derived mammalian alkaloid derivative 1-trichloromethyl-1,2,3,4-tetrahydro-β-carboline...

  • Extrastriatal dopamine D2 receptors in Parkinson's disease: a longitudinal study. Kaasinen, V.; Aalto, S.; NÅgren, K.; Hietala, J.; Sonninen, P.; Rinne, J. O. // Journal of Neural Transmission;Jun2003, Vol. 110 Issue 6, p591 

    Summary. Most antiparkinsonian drugs are known to act through central dopamine D2 receptor agonism. A previous longitudinal positron emission tomography (PET) study has indicated that, in the striatum of Parkinson's disease (PD) patients, dopamine D2 receptor binding declines at a relatively...

  • Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease. Müller, Th.; Benz, S.; Börnke, C.; Russ, H.; Przuntek, H. // Journal of Neural Transmission;Jun2003, Vol. 110 Issue 6, p603 

    Summary. Clinicians use acute challenges with levodopa (LD) and/or apomorphine (A) for diagnostic dopaminergic response tests in Parkinson's disease (PD) patients. We consecutively compared the value of both drugs with performance of repeated ratings and adverse effect recording. Oral...

  • Intact encoding, impaired consolidation in procedural learning in Parkinson’s disease. Cohen, Henri; Pourcher, Emmanuelle // Experimental Brain Research;May2007, Vol. 179 Issue 4, p703 

    Idiopathic Parkinson’s disease (IPD) patients and matched healthy participants were compared on a non-motor procedural task involving semantically related inverted word pairs, and 3 months later to determine the extent of skill consolidation. IPD patients were found to acquire new...

  • Stereotyped behavior or punding in Parkinson's disease. Miwa, Hideto // Journal of Neurology;Sep2007, Vol. 254 Issue S5, p61 

    In patients with Parkinson's disease (PD) disabling repetitive behaviors (stereotyped behaviors or punding) sometimes appear during the course of the illness. Since similar behavioral disorders can be observed in amphetamine and cocaine abusers, excessive dopaminergic tone might have a prominent...

  • Cell death in Parkinson's disease. Maruyama, Wakako; Naoi, Makoto // Journal of Neurology;Sep2002 Supplement 2, Vol. 249, pii06 

    The cause of neuronal cell death in Parkinson's disease is still an enigma. However, recent results obtained by analyses of postmortem brain suggest that a mitochondria-dependent apoptotic signal was activated. The involvement of dopamine-derived endogenous neurotoxin in the pathogenesis of PD...

  • The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson’s disease. Foltynie, Thomas; Lewis, Simon G. J.; Goldberg, Terry E.; Blackwell, Andrew D.; Kolachana, Bhaskar S.; Weinberger, Daniel R.; Robbins, Trevor W.; Barker, Roger A. // Journal of Neurology;Jul2005, Vol. 252 Issue 7, p833 

    Parkinson’s disease (PD) patients show a range of cognitive deficits,which may relate to abnormalities in dopaminergic transmission in fronto–striatal circuitry. In this study, we have investigated the impact of brainderived neurotrophic factor (BDNF) val66met polymorphisms on...

  • Initiation of symptomatic therapy in Parkinson's disease: dopamine agonists versus levodopa. Lev, Nirit; Djaldetti, Ruth; Melamed, Eldad // Journal of Neurology;Sep2007, Vol. 254 Issue S5, p19 

    Parkinson's disease (PD) is a chronic progressive neurodegenerative disease and its early treatment is of prime importance. Early treatment of PD has several goals: to increase the patient's quality of life and to have symptomatic benefits, to slow disease progression, and to prevent...

  • Comparison of α-dihydroergocryptine and levodopa monotherapy in Parkinson’s disease: assessment of changes in DAT binding with [123I]IPT SPECT. Pöpperl, G.; Tatsch, K.; Ruzicka, E.; Storch, A.; Gasser, T.; Schwarz, J. // Journal of Neural Transmission;Aug2004, Vol. 111 Issue 8, p1041 

    Summary. Putative neurotoxic actions of levodopa and neuroprotective effects of dopamine agonists, as indicated by laboratory and animal studies, provide the rationale to study their effect on the progression of Parkinson’s disease. Aim of this pilot study was to compare the effects of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics